Bloomberg -- InterMune Inc. (ITMN), the maker of a drug for a rare lung disease, fell in Nasdaq trading after the company said it isn’t in talks about selling itself.
The shares dropped $2.72, or 5.6 percent, to $45.76 at 11:33 a.m. New York time in Nasdaq Stock Market composite trading. Shares of the Brisbane, California-based company had risen 33 percent this year before today, including a 5 percent gain yesterday after reports InterMune was exploring a sale.
